Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
Baxter (NYSE:BAX) reported fourth-quarter 2025 continuing-operations sales of $2.97 billion (up 8% reported, 3% operational) and a U.S. GAAP net loss from continuing operations of ($1,035) million or ($2.01) per diluted share.
Adjusted diluted EPS from continuing operations was $0.44, down 24% year-over-year. The quarter included a $485 million goodwill impairment and a $330 million valuation allowance on U.S. deferred tax assets. Full-year 2026 adjusted EPS guidance is $1.85–$2.05 with sales expected to be flat to +1%.
Baxter (NYSE:BAX) will host a conference call to discuss fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. Investors can pre-register at the provided registration link to receive call details and access a live webcast via the company's website. The call will be recorded by Baxter and is copyrighted; recording or rebroadcasting by third parties is prohibited without permission.
Baxter (NYSE:BAX) announced on January 13, 2026 the U.S. launch of the Dynamo Series smart stretcher, now available for order and expected to be available during H1 2026. Designed for ED, perioperative and transport use, the Dynamo Series aims to reduce patient transfers with integrated stirrups and a full electric suite for powered drive and positioning. Safety features include Baxter's SafeView+ visual cues, a three-mode bed-exit alarm with auto-rearm, and optional wireless connectivity for EMR and Voalte nurse-call integration. The product offers one of the widest care surfaces in its category and select geographic expansion is planned later in 2026.
MUSC Health and Baxter (NYSE:BAX) announced a multi-year strategic partnership on January 8, 2026 to integrate connected care technologies across MUSC Health’s system.
The collaboration aims to standardize bedside technologies, reduce documentation time, streamline communication, improve nurse satisfaction and retention, enhance quality and safety via real-time insights and advanced monitoring, and support nursing education and scalable best-practice sharing.
Baxter (NYSE:BAX) will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, president and chief executive officer, is scheduled to present at 2:15 p.m. Pacific Time. A live webcast will be available at www.baxter.com and replay access runs through Saturday, July 11, 2026. Investors can watch the live stream or view the replay for Baxter's strategic update and remarks.
Baxter (NYSE:BAX) and The University of Texas Medical Branch presented retrospective analyses of 1.3 million IV infusions using Spectrum IQ large volume pumps, showing improvements after smart pump–EMR integration at six UTMB hospitals over three years (presented at ASHP Dec 7–10, 2025).
Key results: DERS hard alerts -50.3%, soft alerts -30.4%, SSRC alerts -38.1%; median programming time fell from 10s to 4s; alert-resolution times fell ~50% (soft) and 55% (SSRC).
Baxter (NYSE:BAX) announced pricing and terms for cash tender offers for its 2.600% senior notes due 2026 and 1.915% senior notes due 2027. Key figures per $1,000 principal: $990.50 for 2026 notes and $976.61 for 2027 notes; an $30 early tender payment applies.
The 2026 notes outstanding total $750.0M; 2027 notes outstanding total $1,450.0M. The company set a $600M Maximum Tender Cap for 2027s, causing pro rata acceptance of ~56%, and intends to accept $614.37M aggregate principal of 2027 notes for early settlement on Dec. 8, 2025. Total Consideration was determined Dec. 4, 2025 at 10:00 a.m. ET.
Baxter (NYSE:BAX) announced early tender results for its cash offers to repurchase its 2.600% senior notes due 2026 and 1.915% senior notes due 2027. As of the Early Tender Date of Dec. 3, 2025, holders validly tendered $420,589,000 of 2026 Notes and $1,088,660,000 of 2027 Notes against outstanding amounts of $750,000,000 and $1,450,000,000, respectively.
Baxter elected early settlement on Dec. 8, 2025. Total consideration will be set at 10:00 a.m. ET on Dec. 4, 2025 and includes an early tender payment of $30 per $1,000 principal. The company capped purchases of 2027 Notes at $600 million, so accepted 2027 tenders will be pro rated and the company does not expect to accept 2027 tenders after the Early Tender Date.
Baxter (NYSE:BAX) increased the maximum repurchase cap for its 1.915% Senior Notes due 2027 from $300 million to $600 million under its previously announced cash tender offer, for an aggregate $1.45 billion outstanding of those notes. The terms for the separate 2.600% Senior Notes due 2026 tender offer remain unchanged. The Offer to Purchase dated Nov. 19, 2025 governs the Tender Offers, including the applicable portion of the Financing Condition as modified by this press release. Citigroup, BofA Securities and J.P. Morgan are dealer managers; D.F. King is tender and information agent. This press release is not an offer to purchase securities.
Baxter (NYSE:BAX) commenced tender offers on Nov. 19, 2025 to purchase its 2.600% senior unsecured notes due 2026 and a portion of its 1.915% senior unsecured notes due 2027.
The company will fund the offers subject to conditions using proceeds from a concurrent offering of new senior unsecured notes, and intends to use remaining proceeds to repay other indebtedness, including a term loan that had a $645 million outstanding balance as of Sept. 30, 2025.
Key dates: Early Tender Date Dec. 3, 2025; Price Determination Date Dec. 4, 2025; Expiration Dec. 18, 2025; anticipated settlement Dec. 22, 2025.
FAQ
What is the current stock price of Baxter Intl (BAX)?
What is the market cap of Baxter Intl (BAX)?
